Bayer: positive results in refractory chronic cough
(CercleFinance.com) - Bayer today announced that a Phase IIb study showed the efficacy of eliapixant in patients with refractory chronic cough (RCC) with a statistically significant reduction in the number of 24-hour coughs of up to 27% compared to placebo after 12 weeks of treatment.
In the study, eliapixant demonstrated a positive benefit-risk profile, with the vast majority of adverse events considered mild to moderate, the company said, noting that eliapixant may have the potential for safe and effective long-term use.
“Given the high unmet medical need, we are very encouraged with the positive outcome of eliapixant in the chronic cough indication regarding efficacy and safety,” said Christian Rommel, Executive Committee Member of Bayer AG's Pharmaceutical Division and Head of R&D.
Copyright (c) 2021 CercleFinance.com. All rights reserved.